A5057711527- Colorectal Cancer Treatments and Studies
- Oral and Maxillofacial Pathology
- Sarcoma Diagnosis and Treatment
- Neurofibromatosis and Schwannoma Cases
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
Hebei Medical University
2022-2024
Fourth Hospital of Hebei Medical University
2022
Immune checkpoint inhibitors (ICIs) have substantially changed the treatment of a variety malignant tumors. With increasing their usage, unique immune-mediated toxicity profile ICIs has become apparent. We report case esophageal squamous cell carcinoma in patient who received anti-programmed death protein 1 (PD-1) (camrelizumab) therapy and occurrence sequential immune-related adverse events (irAEs). Although many irAEs been reported, severe myositis caused by camrelizumab with simultaneous...
The aim of this study was to establish an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the detection osimertinib in rat plasma, lung and brain tissues. Forty-eight rats were randomly divided into experimental group (receiving at doses 5, 8, 10 mg/kg) a control group. After continuous intragastric administration 15 days, samples blood, lung, tissue collected. Chromatographic separation achieved using BEH C18 column with gradient elution, employing...